Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9773 in Japanese patients with severe sepsis and/or septic shock
NCT01144624Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2010
- Primary completion
- Aug 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AZD9773 in sepsis and septic shock (3 arms), sponsored by AstraZeneca. Primary endpoints: Safety and Tolerability of AZD9773 at 28 days and Pharmacokinetics of AZD9773 at Day 6. Started Jul 2010; status: completed.
02
Drugs
AZD9773
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT01144624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144624.